Evidence map›Paper›PMID 32690063›Full record

ArticleTrials2020

Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial.

Guofa Zhou, Ming-Chieh Lee, Harrysone E Atieli, John I Githure, Andrew K Githeko, James W Kazura, Guiyun Yan

2 registry-linked trialsOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04182126 nacompletednot on this map

Environmental Modifications in Sub-Saharan Africa: Changing Epidemiology, Transmission and Pathogenesis of Plasmodium Falciparum and P. Vivax Malaria

TypeinterventionalSponsorUniversity of California, IrvineRan2019 to 2024Enrolled122,872ConditionsLLIN, PBO LLIN, IRS, LarvicidingArmsRegular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN, Long-lasting microbial larvicide, Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
NCT04565509 nacompletednot on this map

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

TypeinterventionalSponsorWashington University School of MedicineRan2020 to 2024Enrolled1,143ConditionsCovid19, Intellectual Disability, Developmental Disability, Child Development DisorderArmsStandard Messaging, Enhanced Messaging, COVID-19 Testing, Focus Groups, Fuzzy Cognitive Mapping
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Guofa ZhouProgram in Public Health, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-9283-5520
Ming-Chieh LeeProgram in Public Health, University of California, Irvine, CA, USA.
Harrysone E AtieliDepartment of Public Health, Maseno University, Kisumu, Kenya.
John I GithureDepartment of Public Health, Maseno University, Kisumu, Kenya.
Andrew K GithekoKenya Medical Research Institute, Kisumu, Kenya.
James W KazuraCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
Guiyun YanProgram in Public Health, University of California, Irvine, CA, USA. guiyuny@uci.edu.
University of California, Irvine · USMaseno University · KECenter for Global Health · USKenya Medical Research Institute · KE

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
Vector Biology of Invasive Anopheles stephensi in Rural to Urban Landscapes in EthiopiaU19AI129326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Guiyun Yan · 2017 to 2026
$19.9M
Kruppel-Like Factor 2 Counters Vascular and Immunologic Dysfunction in Child Cerebral MalariaR01AI130131 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KAZURA, JAMES WALTER · 2017 to 2021
$3.0M
National Institute of Allergy and Infectious Diseases 3U19AI129326-03S1NIAID NIH HHS R01 AI130131NIAID NIH HHS U19 AI089672NIAID NIH HHS U19 AI129326
6 · The paper itself

Abstract

backgroundIn the past two decades, the massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) has led to significant reductions in malaria mortality and morbidity. Nonetheless, the malaria burden remains high, and a dozen countries in Africa show a trend of increasing malaria incidence over the past several years. This underscores the need to improve the effectiveness of interventions by optimizing first-line intervention tools and integrating newly approved products into control programs. Because transmission settings and vector ecologies vary from place to place, malaria interventions should be adapted and readapted over time in response to evolving malaria risks. An adaptive approach based on local malaria epidemiology and vector ecology may lead to significant reductions in malaria incidence and transmission risk. METHODS/

designThis study will use a longitudinal block-cluster sequential multiple assignment randomized trial (SMART) design with longitudinal outcome measures for a period of 3 years to develop an adaptive intervention for malaria control in western Kenya, the first adaptive trial for malaria control. The primary outcome is clinical malaria incidence rate. This will be a two-stage trial with 36 clusters for the initial trial. At the beginning of stage 1, all clusters will be randomized with equal probability to either LLIN, piperonyl butoxide-treated LLIN (PBO Nets), or LLIN + IRS by block randomization based on their respective malaria risks. Intervention effectiveness will be evaluated with 12 months of follow-up monitoring. At the end of the 12-month follow-up, clusters will be assessed for "response" versus "non-response" to PBO Nets or LLIN + IRS based on the change in clinical malaria incidence rate and a pre-defined threshold value of cost-effectiveness set by the Ministry of Health. At the beginning of stage 2, if an intervention was effective in stage 1, then the intervention will be continued. Non-responders to stage 1 PBO Net treatment will be randomized equally to either PBO Nets + LSM (larval source management) or an intervention determined by an enhanced reinforcement learning method. Similarly, non-responders to stage 1 LLIN + IRS treatment will be randomized equally to either LLIN + IRS + LSM or PBO Nets + IRS. There will be an 18-month evaluation follow-up period for stage 2 interventions. We will monitor indoor and outdoor vector abundance using light traps. Clinical malaria will be monitored through active case surveillance. Cost-effectiveness of the interventions will be assessed using Q-learning. DISCUSSION: This novel adaptive intervention strategy will optimize existing malaria vector control tools while allowing for the integration of new control products and approaches in the future to find the most cost-effective malaria control strategies in different settings. Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination.

trial registrationUS National Institutes of Health, study ID NCT04182126 . Registered on 26 November 2019.

Indexed as

InsecticidesInsecticide-Treated BednetsAdaptive Clinical Trials as TopicAnimalsAnophelesHumansKenyaMalariaMosquito ControlMosquito VectorsRandomized Controlled Trials as TopicInsecticidesActive case surveillanceAdaptive interventionBlock-cluster randomizedClinical malaria incidence rateCost-effectivenessIndoor residual sprayingLarval source managementLong-lasting insecticidal net (LLIN)Piperonyl butoxide-treated LLINQ-learningSequential multiple assignment randomized trial

Identifiers

PMID32690063
PMCPMC7372887
OpenAlexW3043476000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.